Who Paid My Doc
Jason Payne
Clinical Cardiac Electrophysiology Omaha, NE Medical Doctor
NPI 1144420746 CMS profile 1079083
Emile @ 42Nd St, Omaha, NE 68198
General payments
$59,455
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$161,111
Through program year 2025, Jason Payne of Omaha, NE is reported in the CMS Open Payments database as having received $59,455 across 366 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $161,111 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 80th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $23,854 | 121 | |
| 2024 | General | $13,500 | 75 | |
| 2023 | General | $10,555 | 80 | |
| 2022 | General | $2,415 | 25 | |
| 2021 | General | $2,176 | 20 | |
| 2020 | General | $1,843 | 15 | |
| 2019 | General | $5,113 | 30 |
Beside peers
- Jason Payne
- Clinical Cardiac Electrophysiology median
- Middle half of Clinical Cardiac Electrophysiology
- National median
In program year 2025, general payments to Jason Payne were reported at $23,854. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.
Show as a table
| Year | Jason Payne | Clinical Cardiac Electrophysiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,113 | $2,361 | $585–$8,260 | $163 |
| 2020 | $1,843 | $993 | $247–$4,351 | $114 |
| 2021 | $2,176 | $1,185 | $326–$4,739 | $132 |
| 2022 | $2,415 | $2,073 | $554–$6,789 | $149 |
| 2023 | $10,555 | $2,568 | $759–$8,159 | $160 |
| 2024 | $13,500 | $2,557 | $703–$7,403 | $164 |
| 2025 | $23,854 | $2,462 | $733–$7,710 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 19 drugsPart D claims
1,054
Drug cost
$378,041
Branded share of claims
37.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 245 | $275,099 | |
| Xarelto Rivaroxaban | Brand | 53 | $55,790 | |
| Entresto Sacubitril/Valsartan | Brand | 25 | $30,754 | |
| Dofetilide | Generic | 31 | $5,890 | |
| Metoprolol Succinate | Generic | 244 | $3,745 | |
| Amiodarone Hcl | Generic | 120 | $3,437 | |
| Flecainide Acetate | Generic | 32 | $1,179 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 41 | $419 | |
| Sotalol Sotalol Hcl | Brand | 20 | $258 | |
| Carvedilol | Generic | 45 | $254 |
The 10 drugs with the highest cost, of 19 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 64 billing codesPaid by Medicare
$140,114
Medicare patients
1,810
Services billed
3,024
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 55% | |
| Atrial fibrillation | 53% | |
| Ischemic heart disease | 49% | |
| Heart failure | 42% | |
| Chronic kidney disease | 40% | |
| Diabetes | 38% | |
| Depression | 31% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
366 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Cardiac Electrophysiology in Nebraska
Brian Kim
Clinical Cardiac Electrophysiology · Kearney, NE
Hussam Abuissa
Clinical Cardiac Electrophysiology · Omaha, NE
Jeffrey Mahoney
Clinical Cardiac Electrophysiology · Omaha, NE
Shane Tsai
Clinical Cardiac Electrophysiology · Omaha, NE
Grant Wallace
Clinical Cardiac Electrophysiology · Lincoln, NE
Peter Gallagher
Clinical Cardiac Electrophysiology · Lincoln, NE
Related records
Clinical Cardiac Electrophysiology in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Cardiac Electrophysiology
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.